AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis

RecruitingPhase 3Ages 18 Years - 75 YearsAllBeijing InnoCare Pharma Tech Co., Ltd.
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

A randomized, double-blind, placebo-controlled phase III study evaluating the efficacy and safety of oral ICP-332 in subjects with moderate to severe atopic dermatitis

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: 1. Male or female subjects between 18 and 75 years of age. 2. Clinical diagnosis of chronic atopic dermatitis (also known as atopic eczema) for at least 1 year 3. Documented recent history of inadequate response to TCS or TCI, or for whom topical treatments are otherwise medically inadvisable. 4. Subjects must meet the following criteria for disease activity: * Eczema Area and Severity Index (EASI) score โ‰ฅ 16 ; * (Body Surface Area )BSA affected by AD โ‰ฅ 10% ; * (validated Investigator's Global Assessment-AD)vIGA-AD score โ‰ฅ3 ; * Baseline weekly average of daily Worst Pruritus NRS โ‰ฅ 4. 5. Women of childbearing potential (WOCBP) and Men must agree 5\. Women of childbearing potential (WOCBP) and Men must agree to contraception. 6. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. Exclusion Criteria: 1. Lack of response or inadequate response to prior treatment with any JAK inhibitor for AD. 2. Other active skin diseases or skin infections requiring systemic treatment or would interfere with appropriate assessment of atopic dermatitis lesions. 3. Pregnant or breastfeeding females. 4. History of any clinically major diseases, with the exception of atopic dermatitis. 5. Consideration by the Investigator, for any reason, that the subject is an unsuitable candidate to receive ICP-332 or participate in this study.
๐Ÿ’Š

What it tests

  • ICP-332 Tablets
  • ICP-332 Placebo Tablets
๐Ÿ“

Where

62 sites
The First Affiliated Hospital of Anhui Medical University
Hefei, China
The Second Affiliated Hospital of Wannan Medical College
Wuhu, China
Capital Medical University Affiliated Beijing Chaoyang Hospital
Beijing, China
Peking University First Hospital
Beijing, China
Capital Medical University Affiliated Beijing Friendship Hospital
Beijing, China
Peking University Third Hospital
Beijing, China
Beijing Tongren Hospital, Capital Medical University
Beijing, China
Beijing Tsinghua Changgung Hospital
Beijing, China

โ€ฆand 54 more on ClinicalTrials.gov.

๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy